The biosimilars are coming. But how long will it be till they can make their mark?

Emily Wasserman Biosimilars have made a splash in Europe, Australia and India, and now they're gaining steam stateside. That's sure to continue, with Citigroup analysts estimating ...

Nasdaq moves to delist KaloBios in wake of Shkreli bust

John Carroll Just days after kicking Martin Shkreli out as CEO, KaloBios says that Nasdaq plans to delist the company, citing the exec's arrest on fraud and looting charges as one ...

Amgen’s PCSK9 outcomes trial to deliver data sooner than expected

Tracy Staton The wait for outcomes data on Amgen's PCSK9 drug Repatha just got shorter. As CardioBrief reports, top-line results of a study called Fourier will be available in the ...

Australia bets $1B on pricey hep C drugs in broad effort to eradicate the disease

Carly Helfand Good news for Gilead Sciences and Bristol-Myers Squibb: Australia's federal government wants to eliminate hepatitis C in the country. And it plans to shell out $ ...

With Shkreli out, new Turing boss slashes jobs, hunts for a CEO

John Carroll With former Turing founder and CEO Martin Shkreli facing federal fraud and looting charges, the biotech's new helmsman is cutting costs and hunting for someone who'd ...

Valeant’s big pharmacy deal with Walgreens includes quirky drug-buyback plan

Tracy Staton Valeant Pharmaceuticals' much-ballyhooed agreement with Walgreens includes an unusual inventory provision that helps explain why the pharmacy chain might have been ...

Baxalta and Momenta target AbbVie’s blockbuster with positive biosim data

Damian Garde Partners Baxalta and Momenta Pharmaceuticals, among the many contenders looking to challenge the world's top-selling drug, posted positive data for their take on AbbVie's ...

Zoetis hives off 3 manufacturing plants in deal with Bulgarian drugmaker

Tracy Staton Zoetis, under pressure from investors to shape up, laid out a sweeping plan earlier this year to eliminate 10 plants and about 2,500 jobs as part of an effort ...

Pfizer, Merck KGaA launch two more PhIII trials for avelumab

John Carroll The companies say that these two Phase III studies bring the late-stage program up to 6 studies, meeting their goal for 2015. FierceBiotech News

Medicaid would have saved $1.4B with discounts for generics: Report

Emily Wasserman Sen. Bernie Sanders (I-VT) and Rep. Elijah Cummings (D-MD) can add some ammo to their drug price-fighting arsenal, as a new report shows that Medicaid could have saved ...

With Big Pharma backing, eFFECTOR plots solid tumor trial with $40M round

John Carroll More than two years after landing a hefty launch round, San Diego-based eFFECTOR Therapeutics has scooped up a $ 40 million financing from an expanded group of investors, ...

Wings, fries and tacos come first when pharma reps order for docs

Carly Helfand It's all about Southern, American and Mexican food–at least, when pharma reps are ordering in for events at doctors' offices. FiercePharma News
Page 3 of 712345...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS